Mono‐<scp>TKI</scp> and <scp>TKI</scp> Plus <scp>ICI</scp> in Unresectable Hepatocellular Carcinoma Progression on First‐Line Treatment of Lenvatinib: A Real‐World Study
The combination of TKI and ICI presents a promising second-line treatment option after LEN failure, regardless of the specific second-line TKI used.
Authors
- Na Deng (ORCID: https://orcid.org/0000-0002-4557-5372)
- Jinlong Chen (ORCID: https://orcid.org/0000-0002-0320-6755)
- Xue Yin (ORCID: https://orcid.org/0009-0002-6805-4593)
- DING Xiaoyan
Institutions
- Capital Medical University (CN)
- Beijing Ditan Hospital (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/cam4.70711
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00